ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±·¿Ê«æÃ¡¢ÁõÎÄÇÙ¡¢»Æî££©¼¡²ã½þÈóÐÔ°òë×°©£¨MIBC£©Õ¼ËùÓаòë×Äò·ÉÏÆ¤°©±ÈÀýԼΪ25%£¬£¬£¬ÆäÔ¤ºó½Ï²î£¬£¬£¬»¼Õß5ÄêÉúÑÄÂÊȱ·¦50%¡£¡£¡£½üÄêÀ´£¬£¬£¬Ëæ×ÅÃâÒß¼ì²éµãÒÖÖÆ¼ÁµÄ·ºÆð£¬£¬£¬MIBCµÄи¨ÖúÖÎÁÆÈ¡µÃÁËÏÔÖøÏ£Íû¡£¡£¡£
¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîÒ½ÔºÁÖÌìì§½ÌÊںͻƽ¡½ÌÊÚÁìÏεĺ£ÄÚ¶àÖÐÐÄÁÙ´²Ñо¿£¨BGB-A317-2002£©Ì½ÌÖÁËÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÖйúMIBC»¼ÕßµÄÁÆÐ§¡¢Çå¾²ÐÔ¼°Ç±ÔÚµÄÔ¤²âÐÔÉúÎï±ê¼ÇÎï¡£¡£¡£ÕâÏîÑо¿ÎªÖйúMIBC»¼ÕßµÄÖÎÁÆÌṩÁËÖ÷ÒªµÄÑ֤ҽѧ֧³Ö£¬£¬£¬²¢ÓÚ2024Äê9ÔÂ10ÈÕ£¬£¬£¬ÔÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯¡¶Nature Cancer¡·ÉÏ£¬£¬£¬½ÒÏþÁËÌâΪ¡¶Neoadjuvant gemcitabine¨Ccisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial¡±¡·µÄÂÛÎÄ¡£¡£¡£¸ÃÂÛÎĵÄͨѶ×÷ÕßΪÁÖÌìì§¡¢»Æ½¡½ÌÊÚ£¬£¬£¬ÀîïÇÎĸ±Ö÷ÈÎҽʦºÍÖÓÎÄÁúÖ÷ÖÎҽʦΪÅäºÏµÚÒ»×÷Õß¡£¡£¡£

BGB-A317-2002Ñо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢¿ª·Å±êÇ©¡¢µ¥±ÛµÄIIÆÚÁÙ´²ÊÔÑ飬£¬£¬Ö¼ÔÚÆÀ¹ÀÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ¼ªÎ÷Ëû±õ/˳²¬Ð¸¨ÖúÖÎÁÆÔÚÖйúMIBC»¼ÕßÖеÄÓÐÓÃÐÔ¡¢Çå¾²ÐÔ¼°Ô¤²âÉúÎï±ê¼ÇÎï¡£¡£¡£Ñо¿ÓÉngµç×ÓÓÎÏ·ËïÒÝÏɼÍÄîҽԺǣͷ£¬£¬£¬Î÷°²½»Í¨´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº¡¢°²»ÕÒ½¿Æ´óѧµÚ¶þÒ½Ôº¡¢±±¾©´óѧÈËÃñÒ½ÔººÍɽ¶«Ê¡Á¢Ò½ÔºµÈ¶¥¼¶ÃÚÄòÍâ¿ÆÖÐÐÄÅäºÏ¼ÓÈë¡£¡£¡£
Ñо¿µÄÖ÷ÒªÖÕµãΪ²¡ÀíÍêÈ«»º½âÂÊ£¨pCR£©£¬£¬£¬´ÎÒªÖÕµã°üÀ¨ÊÂÎñÎÞÏ£ÍûÉúÑÄ£¨EFS£©¡¢ÎÞ¸´±¬·¢ÑÄ£¨RFS£©¡¢×ÜÉúÑÄÂÊ£¨OS£©¼°Çå¾²ÐԵȡ£¡£¡£ÔÚ57Àý½ÓÊܸùÖÎÐÔÊÖÊõµÄ»¼ÕßÖУ¬£¬£¬pCRÂÊ´ï50.9%£¬£¬£¬ÇкÏÔ¤ÉèµÄͳ¼ÆÑ§Öյ㣬£¬£¬ÌáÐѸÃÖÎÁÆ·½°¸¾ßÓÐÆð¾¢µÄÁÙ´²ÒâÒå¡£¡£¡£×îеÄËæ·ÃÊý¾ÝÏÔʾ£¬£¬£¬1ÄêEFS¡¢OSºÍRFSÂÊ»®·ÖΪ89.3%¡¢91.2%ºÍ85.2%¡£¡£¡£±ðµÄ£¬£¬£¬¸Ãи¨ÖúÖÎÁÆ·½°¸µÄÇå¾²ÐÔºÍÄÍÊÜÐÔÓÅÒì¡£¡£¡£ÉúÎï±ê¼ÇÎïÑо¿ÏÔʾ£¬£¬£¬ÃâÒßÑ×Ö¢±íÐÍ×黼ÕßµÄpCRÂʸߴï80%¡£¡£¡£
ÀúÊ·ÉϵÄи¨Öú»¯ÁÆ·½°¸£¬£¬£¬pCRÂÊ£¨²¡ÀíÍêÈ«»º½âÂÊ£©Í¨³£Îª21%-30%£¬£¬£¬pDSÂÊ£¨²¡Àí½µÆÚÂÊ£©Í¨³£Ð¡ÓÚ50%£¬£¬£¬¶ø±¾Ñо¿µÄpCRºÍpDSÂʽÏÀúÊ·Êý¾Ý¾ùÌá¸ßÁË20%ÒÔÉÏ¡£¡£¡£±ðµÄ£¬£¬£¬±¾Ñо¿ÖÐcT2»¼Õߣ¨ÁÙ´²Õï¶ÏΪT2ÆÚÖ×ÁöµÄ»¼Õߣ©µÄpCRÂʺÍpDSÂÊ»®·ÖµÖ´ï55.6%ºÍ86.1%£¬£¬£¬¸ßÓÚÒÔÍùµÄÑо¿Êý¾Ý¡£¡£¡£Í¬Ê±£¬£¬£¬ÓëÆäËûÃâÒßÁªºÏ˳²¬»¯ÁƵÄÑо¿Ïà±È£¬£¬£¬±¾Ñо¿µÄpCRÂÊ£¨33%-49%£©Ò²ÓâÔ½ÁËÒÔÍùÑо¿µÄÉÏÏÞ¡£¡£¡£
ÖµµÃ×¢ÖØµÄÊÇ£¬£¬£¬±¾Ñо¿Ì½Ë÷ÁËÓëи¨ÖúÃâÒßÁªºÏÖÎÁÆÓ¦´ðÏà¹ØµÄDZÔÚÉúÎï±ê¼ÇÎ£¬£¬È·¶¨ÁËÈýÖÖMIBC£¨¼¡²ã½þÈóÐÔ°òë×°©£©ÑÇÐÍ£º£º£ºS1£¨ÃâÒß»ÄÔ±íÐÍ£©¡¢S2£¨ÃâÒßÇãÔþ±íÐÍ£©ºÍS3£¨ÃâÒßÑ×Ö¢±íÐÍ£©£¬£¬£¬ÏÔʾÁËÔÚи¨ÖúÃâÒß»¯ÁÆÖÐÔ¤²â»ñÒæ»¼ÕßµÄDZÁ¦¡£¡£¡£
±¾Ñо¿Äý¾ÛÁ˺£ÄÚ6¼Ò´óÐÍÃÚÄòÍâ¿ÆÖÐÐĵÄÁÙ´²ÂÄÀú£¬£¬£¬ÀúʱÎåÄ꣬£¬£¬×îÖÕ½ÒÏþÔÚ¡¶Nature Cancer¡·ÕâÒ»¹ú¼Ê¶¥¼¶ÆÚ¿¯ÉÏ¡£¡£¡£ÔÚÁÆÐ§·½Ã棬£¬£¬¸Ã·½°¸ÔÚpCRºÍpDSÂÊÉÏ´¦ÓÚ¹ú¼ÊͬÀàÑо¿µÄÁìÏÈλÖᣡ£¡£Ñо¿ÎªÖйúMIBC»¼Õßи¨ÖúÃâÒßÁªºÏ»¯ÁƵÄÁÙ´²Ó¦ÓÃÌṩÁËÖ÷ÒªµÄÖ¤¾Ý£¬£¬£¬¾ßÓм«´óµÄÁÙ´²Íƹã¼ÛÖµ¡£¡£¡£
ÔÎÄÁ´½Ó£º£º£ºhttps://doi.org/10.1038/s43018-024-00822-0